JY BioMed Collaborates with YC Biotech to Advance Stem Cell-Based Clinical Trial for Alzheimer’s Disease at Taipei Medical University

June 2025 — Taipei

JY BioMed is pleased to announce that, in collaboration with our clinical development partner YC Biotech, we have officially initiated preparations for a stem cell-based clinical trial targeting Alzheimer’s disease at Taipei Medical University. The trial protocol has been commissioned and is progressing steadily toward regulatory submission and formal IRB review.

This clinical trial will investigate the therapeutic potential of mesenchymal stem cells (MSCs) in delaying the progression of Alzheimer’s disease and improving cognitive function. As a leading cause of dementia worldwide, Alzheimer’s disease remains a critical unmet medical need, particularly with a rapidly aging global population. The therapeutic application of MSCs, known for their immunomodulatory and neuroregenerative properties, presents a promising approach to address neurodegeneration and neuroinflammation—two key pathological hallmarks of Alzheimer’s disease.

Under this collaboration, JY BioMed provides the core stem cell technology and serves as the principal developer responsible for manufacturing and regulatory planning. YC Biotech is leading the clinical operations, including trial design, execution logistics, and clinical site coordination. Both parties are committed to ensuring that the trial adheres strictly to international standards of Good Clinical Practice (GCP) and all applicable regulatory frameworks.

“The advancement of this program underscores our shared commitment to translational science and innovative therapies for neurodegenerative diseases,” said a JY BioMed spokesperson. “While there are currently no curative treatments for Alzheimer’s disease, we believe that stem cell-based therapies have the potential to reshape the treatment landscape and bring renewed hope to patients and their families.”

This initiative reflects JY BioMed’s broader mission to expand the clinical applications of regenerative medicine, particularly in challenging indications with high societal and healthcare burdens. Further updates on the trial’s progress will be provided through our official channels.

About JY BioMed

JY BioMed is a biotechnology company dedicated to the research, development, and commercialization of cell- and exosome-based therapeutics for oncology, immunology, and regenerative medicine. Our pipeline includes programs in mesenchymal stem cells (MSCs), dendritic cell cancer vaccines, γδ T cells, NK cell therapy, and antibody-drug conjugates (ADCs), supported by partnerships with leading academic and clinical institutions.

Regulatory Disclaimer The investigational therapy described in this announcement is currently under early clinical development and has not been approved by the U.S. FDA, Taiwan TFDA, or any other regulatory authority for commercial use. All research is conducted in compliance with applicable laws, ethical guidelines, and clinical governance.